P305 - ECE_1719 - High prevalence of deleterious germline variants in cancer risk genes among subjects with young-onset, sporadic pituitary macroadenomas
Aug 2026· European Journal of Endocrinology· Vol 195· 0 citations
TL;DR
The identification of a high rate of deleterious germline variants in cancer-risk genes in pituitary adenomas echoes similar findings in young patients across a wide range of tumors affecting other organs.
Abstract
Pituitary adenomas are common intracranial tumors, clinically affecting 1:1000 individuals and most cases remain genetically unexplained. Emerging research has highlighted the major contribution of germline pathogenic variants to tumorigenesis across many tissue types in young subjects. We investigated whether young-onset (<30 years old) pituitary macroadenomas that were negative for known genetic causes harbor pathogenic or likely pathogenic (P/LP) variants in a panel of >200 cancer-risk genes.
We retrospectively analyzed 60 subjects (36 males; 95% GH- or PRL-secreting) with sporadic pituitary macroadenomas that were negative for known germline variants (AIP, MEN1, CDKN1B) or duplications (GPR101). Whole-exome sequencing (WES) was performed on germline DNA. Bioinformatics analysis including variant calling (for small variants and CNVs), annotation and variant prioritization were performed, using secondary analysis pipelines for WES data and a certified diagnostics predictor platform (AION) for tertiary analysis. Variants in established cancer-risk genes were prioritized.
P/LP germline variants in 22 different cancer-risk genes were identified in 16.7% of subjects on ClinVar/ACMG criteria. This rose to 35.0% of subject with deleterious variants when additional in silico and AION predictor criteria were included.
Our findings expand the spectrum of genes potentially associated with young-onset pituitary macroadenomas. The identification of a high rate of deleterious germline variants in cancer-risk genes in pituitary adenomas echoes similar findings in young patients across a wide range of tumors affecting other organs. These results may have relevance for genetic counseling and potentially could expand targeted management strategies in young patients with large pituitary tumors.
Assessment of the role of germline CHEK2 variants in the development of different cancer types confirmed that CHEK2 c.470T>C is the most common variant in the patient group, and the contribution of this variant to hereditary cancer risk in the Russian population is modest.
M. Nemtsova, M. Makarova, Anastasiia M. Danishevich et al.· International Journal of Mol...· 0 citations
This study investigated germline genetic variants in 165 Tunisian breast cancer patients using targeted next-generation sequencing of a multigene cancer panel to identify pathogenic or likely pathogenic variants in BRCA1 and BRCA2 genes and identified P/LPVs in other genes.
N. Ammous-Boukhris, Rania Abdelmaksoud-Dammak, W. Ben Kridis et al.· Cancers· 0 citations
A systematic discovery pipeline focused on families with multiple affected individuals, leveraging familial segregation and matched tumor analysis to identify novel hereditary PDAC susceptibility genes, highlighting the complexity of hereditary PDAC and support continued genetic and functional evaluation of the priorit...
Jing-Xiong Xu, Y. Goldberg, Amy Zhang et al.· Cancer Research· 0 citations
It is demonstrated that somatic rather than germline risk predominates in middle-aged healthy adults and the VAF-haplotype-sharing analysis framework provides a scalable framework for variant classification in large-scale population genomics.
H. A. MacGregor, J. Blundell, D. Easton· medRxiv· 0 citations
Although a heritable component is implicated in ~10% of melanomas, the prevalence and functional relevance of germline pathogenic variants (gPVs) in unselected patients remains unknown. We evaluated 701 patients with melanoma who underwent tumor-normal MSK-IMPACT sequencing (2015–2023) and germline analysis of ≥76 ca...
S. Lochrin, H. Walch, Y. Kemel et al.· npj Genomic Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.